Biomed. Papers 145(2), 61-64 (2001) | DOI: 10.5507/bp.2001.013

OSTEOPROTEGERIN, RANK, RANKL

David Stejskala, Josef Bartekb, Radmila Pastorkováa, Viktor Růžičkaa, Ivo Orala, Dalimil Horalíka
a Department of Laboratory Medicine and Internal Medicine, Hospital Šternberk
b Institute of Medical Chemistry and Biochemistry, Palacký University, 775 15 Olomouc

Osteoprotegerin, RANK (Receptor Activator of Nuclear factor kappa B) and RANKL (Receptor Activator ofNuclear faktor kappa B ligand) became the aim of intensive researche. RANK is considered as a hematopoieticsurface receptor controling osteoclastogenesis and calcium metabolism. RANKL may promote osteoresorption byinduction of cathepsin K gene expression. The present paper summarizes the most significant data in osteoprotegerin,RANK and RANKL problems obtained.

Keywords: Osteoprotegerin, RANK, RANKL

Received: January 10, 2002; Published: December 1, 2001  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Stejskal, D., Bartek, J., Pastorková, R., Růžička, V., Oral, I., & Horalík, D. (2001). OSTEOPROTEGERIN, RANK, RANKL. Biomedical papers, 145(2), 61-64. doi: 10.5507/bp.2001.013
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Shalhoub, V., Faust, J., Boyle, W. J. et al. (1999) Osteoprotegerin and osteoprotegerin ligand Effects on Osteoclasts formation from human peripheral blood mononuclear cell precursors. J. Cell. Biochem., 72, 251-261. Go to original source... Go to PubMed...
    2. Browner, W. B., Li-Yang, Lui, Cummingsa, S. R. (2001) Associations of Serum Osteoprotegerin Levels With Diabetes, Stroke, Bone density, fractures and mortality in Elderly Women. The J. of Clin. Endocrinology and Metabolism, 86, 631-637. Go to original source...
    3. Zhang, Y., Heulsmann, A., Tondravi, M. M. (2001) TNF-alpha Stimulates RANKL-inducer osteoclastogenesis via coupling of TNF type 1 receptor and RANK Signaling Pathways. J. Biol. Chem., 276, 563-568. Go to original source... Go to PubMed...
    4. Hofbauer, L. C., Gori, F., Riggs, B. L. et al. (1999) Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucorticoids ih human osteoblastic lineage cells. Endocrinology, 140, 4282-4289. Go to original source... Go to PubMed...
    5. Hofbauer, L. C., Khosla, S., Dunstan, C. R. et al. (1999) Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology, 14, 4367-4370. Go to original source... Go to PubMed...
    6. Kaneda, T., Nojima, T., Nakagawa, M. (2000) Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. J. Immunol., 165, 4254-4263. Go to original source... Go to PubMed...
    7. Haltner, W. J.: The effect of a single dose of osteoprotegerin in postmenopausal women. J. Bone. Res., 16, 348-360.
    8. Aubin, J. E., Bonnelye, E. (2000) Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. Osteoporos. Int., 11, 905-13. Go to original source... Go to PubMed...
    9. Kostenuik, P. J., Shalhoub, V. (2001) Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. Curr. Pharm. Des., 7, 613-35. Go to original source... Go to PubMed...
    10. Suda, T., Takahashi, N., Udagawa, N., Jimi, E., Gillespie, M. T., Martin, T. J. (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev., 3, 345-57. Go to original source... Go to PubMed...
    11. Haynes, D. R., Crotti, T. N., Potter, A. E., Loric, M., Atkins, G. J., Howie, D. W., Findlay, D. M. (2001) The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis. J. Bone. Joint. Surg. Br., 6, 902-11. Go to original source... Go to PubMed...
    12. Hofbauer, L. C., Neubauer, A., Heufelder, A. E. (2001) Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer, 92, 460-70. Go to original source... Go to PubMed...
    13. Chikazu, D., Katagiri, M., Ogasawara, T., Ogata, N., Shimoaka, T., Takato, T., Nakamura, K., Kawaguchi, H. (2001) Regulation of osteoclast differentiation by fibroblast growth factor 2: stimulation of receptor activator of nuclear factor kappaB ligand/ osteoclast differentiation factor expression in osteoblasts and inhibition of macrophage colony-stimulating factor function in osteoclast precursors. J. Bone. Miner. Res., 11, 2074-81. Go to original source... Go to PubMed...
    14. Yano, K., Nakagawa, N., Yasuda, H., Tsuda, E., Higashio, K. (2001) Synovial cells from a patient with rheumatoid arthritis produce osteoclastogenesis inhibitory factor/osteoprotegerin: reciprocal regulation of the production by inflammatory cytokines and basic fibroblast growth factor. J. Bone. Miner. Metab., 6, 365-72. Go to original source... Go to PubMed...
    15. Jung, K., Lein, M., von Hosslin, K., Brux, B., Schnorr, D., Loening, S. A., Sinha, P. (2001) Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. Clin. Chem. 11, 2061-3. Go to original source...
    16. Price, P. A., June, H. H., Buckley, J. R., Williamson, M. K. (2001) Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Rev. Invest. Clin., 4, 362-9. Go to original source...
    17. Brown, J. M., Vessella, R. L., Kostenuik, P. J., Dunstan, C. R., Lange, P. H., Corey, E. (2001) Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin. Cancer. Res. 10, 2977-83.
    18. Yano, K., Shibata, O., Mizuno, A., Kobayashi, F., Higashio, K., Morinaga, T., Tsuda, E. (2001) Immunological study on circulating murine osteoprotegerin/osteoclastogenesis inhibitory factor (opg/ocif): possible role of opg/ocif in the prevention of osteoporosis in pregnancy. Biochem. Biophys. Res. Commun., 288, 217-24. Go to original source... Go to PubMed...
    19. Feuerherm, A. J., Borset, M., Seidel, C., Sundan, A., Leistad, L., Ostensen, M., Faxvaag, A. (2001) Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. Scand. J. Rheumatol., 30, 229-34. Go to original source... Go to PubMed...
    20. Sato, T., Tominaga, Y., Iwasaki, Y., Kazama, J. J., Shigematsu, T., Inagaki, H., Watanabe, I., Katayama, A., Haba, T., Uchida, K., Fukagawa, M. (2001) Osteoprotegerin levels before and after renal transplantation. Am. J. Kidney Dis., 38, Suppl. 1, 175-7. Go to original source...
    21. Kazama, J. J., Maruyama, H., Gejyo, F. (2001) Osteoclastogenesis and osteoclast activation in dialysis-related amyloid osteopathy. Am. J. Kidney Dis., 38, Suppl. 1, 156-60. Go to original source...
    22. Seidel, C., Hjertner, O., Abildgaard, N., Heickendorff, L., Hjorth, M., Westin, J., Nielsen (2001) Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98, 2269-71. Go to original source... Go to PubMed...
    23. Kostenuik, P. J., Capparelli, C., Morony, S., Adamu, S., Shimamoto, G., Shen, V., Lacey, D. L., Dunstan, C. R. (2001) OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. Endocrinology, 142, 4295-304. Go to original source... Go to PubMed...
    24. Pearse, R. N., Sordillo, E. M., Yaccoby, S., Wong, B. R., Liau, D. F., Colman, N., Michaeli, J., Epstein J., Choi, Y. (2001) Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc. Natl. Acad. Sci. U. S. A., 98, 11581-6. Go to original source... Go to PubMed...
    25. Tintut, Y., Demer, L. L. (2001) Recent advances in multifactorial regulation of vascular calcification. Curr. Opin. Lipidol., 12, 555-60. Go to original source... Go to PubMed...
    26. McCauley, L. K. (2001) Transgenic mouse models of metabolic bone disease. Curr. Opin. Rheumatol., 13, 316-25. Go to original source... Go to PubMed...
    27. Ma, Y. L., Cain, R. L., Halladay, D. L., Yang, X., Zeng, Q., Miles, R. R., Chandrasekhar, S., Martin, T. J., Onyia, J. E. (2001) Catabolic effects of continuous human PTH (1-38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology, 142, 4047-54. Go to original source... Go to PubMed...
    28. Hofbauer, L. C., Heufelder, A. E. (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J. Mol. Med., 79, 243-53. Go to original source... Go to PubMed...
    29. Thirunavukkarasu, K., Miles, R. R., Halladay, D. L., Yang, X., Galvin, R. J., Chandrasekhar, S., Martin, T. J., Onyia, J. E. (2001) Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J. Biol. Chem., 276, 36241-50. Go to original source... Go to PubMed...
    30. Corisdeo, S., Gyda, M., Zaidi, M., Moonga, B. S., Troen, B. R. (2001) New insights into the regulation of cathepsin K gene expression by osteoprotegerin ligand. Biochem. Biophys. Res. Commun., 285, 335-9. Go to original source... Go to PubMed...
    31. Szulc, P., Hofbauer, L. C., Heufelder, A. E., Roth, S., Delmas, P. D. (2001) Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J. Clin. Endocrinol. Metab., 86, 3162-5. Go to original source... Go to PubMed...
    32. Morony, S., Capparelli, C., Sarosi, I., Lacey, D. L., Dunstan, C. R., Kostenuik, P. J. (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer. Res., 61, 4432-6.

    Return to the content